Login / Signup

Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis.

Nabil F SabaRitu ChaudharyKedar S KirtaneAngelo MarraAsari EkpenyongAshley Alesia McCookNicole C SchmittJennifer H GrossMihir R PatelJill RemickJames E BatesMark W McDonaldSoumon F RudraWilliam A StokesMaria I PooleXiaofei SongRobbert J C SlebosYuan LiuConor E SteuerDong M ShinYong TengChristine H Chung
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Pembrolizumab and cabozantinib provided prolonged encouraging long-term disease control and survival with a maintained favorable safety profile. The prognostic significance of increased CD8+, CD103+ and CSF1-R+ cell density in TIME deserve further evaluation in similar clinical settings.
Keyphrases
  • advanced non small cell lung cancer
  • squamous cell carcinoma
  • single cell
  • small cell lung cancer
  • metastatic renal cell carcinoma
  • cell therapy
  • stem cells
  • epidermal growth factor receptor
  • mesenchymal stem cells